Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Bone and Joint Surgery. American Volume|March 1, 1976
Recurrent anterior dislocation of the shoulder. Long-term follow-up of the Putti-Platt and Bankart proceduresB F Morrey, J M Janes
Lymphology|March 1, 1977
Lymphedema: results of surgical treatment in 64 patients (1936-1964)S B Sakulsky, A Schirger, E G Harrison, et al.
Diabetes/Metabolism Research and Reviews|September 7, 2001
Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulinS C Ferguson, M W Strachan, J M Janes, et al.
The Journal of Bone and Joint Surgery. American Volume|September 25, 2009
The effect of high-dosage ultrasonic energy on femora of the dog: a roentgenographic, histological, and microangiographic studyJ M JANES, P J KELLY, J F HERRICK, et al.
Minerva Anestesiologica|June 30, 2012
Do established prognostic factors explain the different mortality rates in ICU septic patients around the world?E Silva, A B Cavalcanti, D D G Bugano, et al.
Diabetes Care|December 5, 1998
The action profile of lispro is not blunted by mixing in the syringe with NPH insulinS E Joseph, A Korzon-Burakowska, J R Woodworth, et al.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
Infection|May 1, 2009
Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registryR Beale, K Reinhart, F M Brunkhorst, et al.
The Pharmacogenomics Journal|February 8, 2012
Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsisM Man, S L Close, A D Shaw, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
Pageof 1